Author

Ravi K. Narra

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety, tolerability, and pharmacokinetics (PK) of luspatercept (LUSPA) at increased injection volumes (up to 2 mL) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) who require red blood cell (RBC) transfusions: Results from MAXILUS.

531 Background: LUSPA is approved for anemia in adults with LR-MDS who are erythropoiesis-stimulating agent (ESA)-naive or have had prior ESA failure and require RBC transfusions. At previously FDA-approved 1.2 mL syringe volume cap, LUSPA 1.75 mg/kg dosing requires multiple subcutaneous (SC) injections across...

Ali McBride, Krzysztof Mądry, Luke Fletcher et al. · JCO Oncology Practice · 0 citations

Open access Sep 2026

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).

H. Mian, M. Faisal, Tie-Ning Chen et al. · Cancer · 0 citations

Review Open access Aug 2026

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Results support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis and support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis.

S. Dorbala, Mathew S. Maurer, S. Cuddy et al. · Journal of the American Medi... · 0 citations